Compare Honda Motor Company Ltd. Common Stock (HMC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honda Motor Company Ltd. Common Stock vs Tango Therapeutics Inc. — how do they compare? Honda Motor Company Ltd. Common Stock trades at $33.67 (market cap $43.65B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Honda Motor Company Ltd. Common Stock is far larger — about 11.7× Tango Therapeutics Inc.'s market cap, and Honda Motor Company Ltd. Common Stock pays a 3.98% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honda Motor Company Ltd. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| HMC | TNGX | |
|---|---|---|
Market Cap | $43.65B | $3.74B |
Volume | 707,941 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $33.45 | $32.90 |
52-Week Low | $23.49 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $40.82B | $2.76B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honda Motor Co. (HMC) trades at $33.33, up 2.05% with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with revenue growth to $22.5T in 2026 but negative net income margins, while valuation metrics appear attractive with P/S of 0.32 and EV/EBITDA of 4.92. Recent news highlights strategic investments in hybrid technology and cost-cutting initiatives.
HMC presents a value opportunity with reasonable valuations and positive earnings surprises, though profitability challenges and competitive pressures create headwinds. Analyst consensus leans moderate buy with institutional interest, but investors should weigh cost reduction progress against margin pressures in the evolving auto industry.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honda Motor Company Ltd. Common Stock
Honda Motor manufactures automobiles, motorcycles, power products, and related financial services. Its brands serve consumer and commercial transportation markets globally.
Read more on HMC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
